Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies.

Bex A, Larkin J, Voss M.

Am Soc Clin Oncol Educ Book. 2015:e239-47. doi: 10.14694/EdBook_AM.2015.35.e239. Review.

2.

Systemic therapies for metastatic renal cell carcinoma in older adults.

Pal SK, Vanderwalde A, Hurria A, Figlin RA.

Drugs Aging. 2011 Aug 1;28(8):635-49. doi: 10.2165/11592880-000000000-00000. Review.

3.

The role of targeted therapy in metastatic renal cell carcinoma.

Unnithan J, Rini BI.

ScientificWorldJournal. 2007 Mar 2;7:800-7. Review.

4.

Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.

Raman R, Vaena D.

Biomed Res Int. 2015;2015:367354. doi: 10.1155/2015/367354. Epub 2015 Jun 16. Review.

5.

Novel molecular targets for the therapy of renal cell carcinoma.

Elfiky AA, Sonpavde G.

Discov Med. 2012 Jun;13(73):461-71.

6.

Recent progress in the management of advanced renal cell carcinoma.

Garcia JA, Rini BI.

CA Cancer J Clin. 2007 Mar-Apr;57(2):112-25. Review.

PMID:
17392388
7.

Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.

Badal SAM, Aiken WD, Chin SN.

Curr Drug Targets. 2017;18(10):1204-1213. doi: 10.2174/1389450117666160502152518. Review.

PMID:
27138755
8.

Systemic therapy in renal cell carcinoma: advancing paradigms.

Posadas EM, Figlin RA.

Oncology (Williston Park). 2012 Mar;26(3):290-301. Review.

9.

Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Hernandez-Yanez M, Heymach JV, Zurita AJ.

Curr Oncol Rep. 2012 Jun;14(3):221-9. doi: 10.1007/s11912-012-0231-2. Review.

10.

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.

Mihaly Z, Sztupinszki Z, Surowiak P, Gyorffy B.

Curr Cancer Drug Targets. 2012 Sep;12(7):857-72. Review.

11.

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S.

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 1:S1-29.

12.

Current management and future perspectives of metastatic renal cell carcinoma.

Lee-Ying R, Lester R, Heng D.

Int J Urol. 2014 Sep;21(9):847-55. doi: 10.1111/iju.12502. Epub 2014 May 27. Review.

13.

Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.

PMID:
28410911
14.

Adjuvant therapy for advanced renal cell carcinoma.

Meissner MA, McCormick BZ, Karam JA, Wood CG.

Expert Rev Anticancer Ther. 2018 Jul;18(7):663-671. doi: 10.1080/14737140.2018.1469980. Epub 2018 May 2. Review.

PMID:
29707987
15.

Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

Albiges L, Molinie V, Escudier B.

Oncologist. 2012;17(8):1051-62. doi: 10.1634/theoncologist.2012-0038. Epub 2012 Jul 17. Review.

16.

New agents in renal cell carcinoma.

Dabney R, Devine R, Sein N, George B.

Target Oncol. 2014 Sep;9(3):183-93. doi: 10.1007/s11523-013-0303-8. Epub 2013 Nov 16. Review.

PMID:
24243495
17.

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.

Cho D, Signoretti S, Regan M, Mier JW, Atkins MB.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s. Review.

18.

Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.

Zibelman M, Plimack ER.

J Natl Compr Canc Netw. 2017 Jun;15(6):841-847. doi: 10.6004/jnccn.2017.0103. Review.

PMID:
28596263
19.

Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.

Cohen RB, Oudard S.

Invest New Drugs. 2012 Oct;30(5):2066-79. doi: 10.1007/s10637-012-9796-8. Epub 2012 Feb 12. Review.

20.

[Medical therapies for locally advanced/metastatic kidney cancer].

Afrit M, Yahyaoui Y, Bouzouita A, Hantous S, Labidi S, Chebil M, Ben Miled K, Escudier B, Boussen H.

Presse Med. 2015 Feb;44(2):135-43. doi: 10.1016/j.lpm.2014.07.020. Epub 2014 Dec 18. Review. French.

PMID:
25535168

Supplemental Content

Support Center